We Might Have A New Metabolism Drug!
Why Pharma is Where Real Longevity Is Being Solved And Why You Should Be Excited!
The popular believe is that longevity is wellness. The word is starting to get so over used that, it often overshadows the real news that need attention - biopharma breakthroughs and possibilities.
Longevity breakthroughs are happening in two specific categories of biopharma, and both are accelerating. One gets all the venture money and takes a decade. The other gets almost nothing and could move in years. Together, they represent the actual opportunity landscape in aging.
So lets talk about it.
The Two Moonshots
Category One: Novel Drug Discovery
This is the visible moonshot. You build a brand new molecule from scratch, prove it works in humans, and change the biology of aging itself.
ATX-304 from Cambrian Bio (and our advisor James Peyer, PhD) is the current proof point. First-in-class AMPK Network Activator. It’s not a weight loss drug. It’s a metabolism drug. The distinction matters. When added to GLP-1 receptor agonists, ATX-304 substantially increases weight loss while completely protecting against lean mass reduction.
That’s the move. GLP-1s are powerful but they come with a fatal flaw: discontinuation. Patients lose the drug, metabolic function crashes, weight returns. ATX-304 as a maintenance agent holds metabolic improvements in place when patients stop GLP-1 treatment and return to normal life. It’s the metabolic foundation GLP-1s need but don’t have. This is the longevity angle. You’re not chasing thinness. You’re protecting metabolic function as a biomarker of aging.
Now in Phase 2 trials. This path is slow. It costs hundreds of millions. It takes 10 to 15 years from concept to prescription. But when it works, it’s a moat. It’s proprietary. It’s a business.
And James himself is one of a kind scientist - I am rooting loudly for this one, and one I will definitely take once it clear human trials!
Category Two: Drug Repurposing
This is the invisible moonshot. You take a drug already approved by the FDA for one disease, and you discover it extends lifespan or improves healthspan more broadly.
GLP-1 receptor agonists are the most exciting proof point. Semaglutide was approved for type 2 diabetes in 2009. Liraglutide followed. These drugs do one thing really well: they regulate glucose and hunger signaling. Then people noticed something else. The drugs worked for weight loss. Not because of calorie restriction. Because they change metabolic biology fundamentally. Now there’s credible evidence they improve cardiometabolic aging, reduce inflammation, and potentially slow biological aging itself. A drug approved for diabetes in 2009 is being tested for longevity in 2026. That’s the repurposing playbook at maximum velocity.
Eric Verdin at the Buck Institute runs the NIH’s Interventions Testing Program. His lab systematically tests whether FDA-approved drugs extend lifespan. Rapamycin: 9 to 26 percent lifespan extension across mouse strains. Acarbose: roughly 20 percent in males, 5 percent in females. 17-alpha-estradiol: 19 percent lifespan extension in males. These aren’t theoretical. They’re documented. All off-patent. All already in the pharmacy.
Andrea Maier ex-Buck Institute, Chi Longevity Founder studied metformin as a longevity candidate. The data is clear: metformin is powerful for treating type 2 diabetes. But for healthy aging? She found no convincing evidence it slows biological aging in people without diabetes.
Key metformin insight: a drug highly effective for treating disease is not automatically the best intervention for healthy individuals. This is the nuance repurposing requires.
The repurposing path is fast. It’s cheap. A Phase 2 trial costs millions, not hundreds of millions. You already know safety. You already have manufacturing. The problem is incentive. If you can’t patent it, venture capital doesn’t exist for it. If venture doesn’t exist, funding doesn’t exist. The drug sits in the pharmacy doing one job when it could be doing another. GLP-1 agonists got lucky. They got attention. Most don’t.
Why Both Paths Matter
Novel drug discovery is powerful but constrained by time and capital. Repurposing is efficient but constrained by incentive. Together, they cover the actual surface area of what’s possible.
Novel drugs let you engineer specificity. You can build a molecule that does exactly one thing: activate AMPK in peripheral tissue to improve metabolic function without systemic side effects, like ATX-304. You can’t do that with rapamycin. But you also can’t do that with zero funding.
Repurposing lets you move faster. You skip animal models. You skip early-phase safety. You move straight to efficacy in humans. And you do it for a fraction of the cost. But you need scientists, trials, and publications to make it visible. The system doesn’t fund that work.
The Skin Longevity Play
Here’s where it gets interesting. Both paths can coexist in the same company, the same product category, even the same molecule.
Rapalogix Health just raised $20 million in Series A funding (Woodline Partners and GordonMD Global Investments) to commercialize skin longevity based on rapamycin biology - topically!
But they’re not repurposing rapamycin directly. They’re taking the biological mechanism that rapamycin revealed (selective TORC1 modulation), engineering a proprietary new molecule (RLX-201) optimized specifically for skin, and selling it as a serum (Re-Q Pro-Longevity Face Serum) alongside clinical validation.
This is the hybrid play. It takes the speed and biological clarity of repurposing (we know what works, we know the mechanism, we have 20+ years of safety data). But it wraps it in the proprietary protection of a new molecule so you can actually fund it at venture scale and build a business that doesn’t collapse the moment the patent expires.
The category is fragmenting. You’ve got boutique dermatology clinics building diagnostic infrastructure around skin microbiome and aging markers. You’ve got consumer brands selling “longevity serums” with zero clinical backing. You’ve got investors looking at skin as the most accessible biomarker for systemic aging. And now you’ve got venture-backed companies taking the biology that works and engineering it into defensible, scalable products.
Rapalogix is betting that longevity is moving from the lab to the clinic to the consumer. That rapamycin biology — which extends lifespan in mice and is being tested for healthspan in humans — has a near-term application in skin. That women (and men) will pay for a serum calibrated to actual aging biology, not just marketing copy. And that the path from pharmaceutical mechanism to skincare consumer product is shorter than the path from novel molecule to FDA approval.
They’re probably right.
Why Both Are Blocked
Novel Discovery Is Blocked By Time
A first-in-class molecule takes a decade minimum. Patent protection is 20 years from filing, which often means 12 to 15 years of actual exclusivity. By the time you reach the clinic, you’ve burned a billion dollars. By the time you reach profitability, the patent is half-expired.
Venture capital is optimized for 7 to 10 year exits. Longevity drugs are 15 to 20 year businesses. The math doesn’t work unless you’re willing to take longer-term capital, which exists but is rare. Most companies are forced to sell too early or die trying.
Regulatory friction is real. The FDA doesn’t have a clear pathway for “extends lifespan in healthy humans.” You have to proxy it with biomarkers or disease states. That takes time. That costs money. That creates friction.
Repurposing Is Blocked By Economics
You can’t patent a drug that’s already off-patent. If you discover rapamycin extends lifespan, you can’t charge $50,000 a year for it. You can charge dollars. Maybe tens of dollars. That doesn’t fund a $500 million venture fund.
Pharmaceutical companies won’t fund repurposing of their own off-patent drugs because they make nothing on it. They make money on new molecules they control. Why would Pfizer fund a rapamycin trial when they already own the compound and can’t increase the price? There are 3,000 FDA-approved drugs in the pharmacy. Most have been tested for one disease at one dose. That’s roughly 10,000 diseases. Most drug-disease pairs have never been tried. The opportunity is literally shelved.
Grant funding exists, but it’s not venture. It’s academic. Academic funding moves slower. Academic publishing takes time. Academic science isn’t optimized for speed or scale. A repurposing opportunity that could be validated in three years takes seven.
Incentive structure is the real blocker. The system is architected to ignore what’s already working.
Why AI Changes Both
AI accelerates novel discovery by collapsing the timeline for molecule design. Instead of five years of chemistry to hit a target, you might do it in six months. Instead of trying 10,000 molecules, AI helps you try 100,000. And it helps you predict which will actually work in humans before you spend a billion dollars.
AI accelerates repurposing by mining clinical data and published literature at scale. Machine learning can scan decades of FDA adverse event reports, EHR data, and trial databases to find signals nobody else noticed. A drug approved for hypertension 20 years ago might have hidden telomere extension data buried in an obscure trial from 2003. AI finds those signals. Then humans validate them.
Both paths get faster. Both paths get cheaper. The constraint changes from “can we do this” to “will we fund this.”
The moonshots are real. Both of them. One gets funded. One gets ignored. One gets hybrid. Together, they represent the actual longevity playbook. And AI is making all three paths move faster than they ever have.
If this gave you something to think about, pass it on. Restack it for someone who’d argue with you, reply and tell me where you land, or subscribe if you’re new here. I read everything.
In Search Of is where I chase the questions the wellness industry is too sure about.
Appendix
James Peyer, “Cambrian Bio’s AMPK Network Activator ATX-304 Boosts Human Metabolic Function,” LinkedIn Pulse
Verdin Lab, NIH Interventions Testing Program (rapamycin, acarbose, estradiol lifespan data)
Andrea Maier, Buck Institute (metformin for healthy aging analysis)
GLP-1 receptor agonist longevity mechanistic data
Cambrian Bio ATX-304 Phase 1b and Phase 2 data
Rapalogix Series A press release — Woodline Partners, GordonMD Global Investments LP
RLX-201 mechanism and Re-Q formulation